Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Prostaglandin ethanolamides attenuate damage in a human explant colitis model|
|Citation:||Prostaglandins & Other Lipid Mediators, 2013; 100(1):22-29|
|Lauren L. Nicotra, Megan Vu, Benjamin S. Harvey and Scott D. Smid|
|Abstract:||Endocannabinoids are protective in animal colitis models. As endocannabinoids also form novel prostaglandin ethanolamides (prostamides) via COX-2, we investigated the effects of prostamides and other COX-2 mediators on tissue damage in an ex vivo human mucosal explant colitis model. Healthy human colonic mucosae were incubated with pro-inflammatory cytokines TNF-α and IL-1β to elicit colitis-like tissue damage. The PGF-ethanolamide analogue, bimatoprost decreased colitis scores which were reversed by a prostamide-specific antagonist AGN 211334, but not the FP receptor antagonist AL-8810. PGF-ethanolamide and PGE-ethanolamide also reduced cytokine-evoked epithelial damage. Anandamide was protective in the explant colitis model; however COX-2 inhibition did not alter its effects, associated with a lack of COX-2 induction in explant mucosal tissue. These findings support an anti-inflammatory role for prostamides and endocannabinoids in the human colon.|
|Keywords:||Colon, Sigmoid; Humans; Colitis; Amides; Sulfonamides; Oxazoles; Arachidonic Acids; Dinoprostone; Dinoprost; Cloprostenol; Tumor Necrosis Factor-alpha; Receptors, Prostaglandin; Cyclooxygenase Inhibitors; Endocannabinoids; Tissue Culture Techniques; Immunohistochemistry; Adult; Middle Aged; Female; Male; Cyclooxygenase 2; Polyunsaturated Alkamides; Interleukin-1beta; Young Adult; Bimatoprost|
|Rights:||© 2013 Elsevier Inc. All rights reserved.|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.